ImmuCell Corporation Asset Resilience Ratio
ImmuCell Corporation asset resilience ratio. ImmuCell Corporation (ICCC) has an Asset Resilience Ratio of 0.11% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ImmuCell Corporation (ICCC) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ImmuCell Corporation (2002–2021)
Asset resilience ratio of ImmuCell Corporation from 2002 to 2021. This chart shows how ImmuCell Corporation's Asset Resilience Ratio has changed over time. Read ICCC total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ImmuCell Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ICCC total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.40K | 0.11% |
| Total Liquid Assets | $50.40K | 0.11% |
Asset Resilience Insights
- Limited Liquidity: ImmuCell Corporation maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ImmuCell Corporation Industry Peers by Asset Resilience Ratio
Compare ImmuCell Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
ImmuCell Corporation Asset Resilience Ratio by Year (2002–2021)
ImmuCell Corporation asset resilience ratio by year from 2002 to 2021. The table below shows the annual Asset Resilience Ratio data for ImmuCell Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $-468.00 | $44.47 Million | -2.47pp |
| 2020-12-31 | 2.47% | $996.50K | $40.35 Million | -3.94pp |
| 2019-12-31 | 6.41% | $2.48 Million | $38.69 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $34.30 Million | -- |
| 2016-12-31 | 22.16% | $5.47 Million | $24.70 Million | -8.41pp |
| 2015-12-31 | 30.57% | $4.46 Million | $14.60 Million | +8.05pp |
| 2014-12-31 | 22.52% | $2.49 Million | $11.05 Million | -4.71pp |
| 2013-12-31 | 27.23% | $2.98 Million | $10.96 Million | +6.93pp |
| 2012-12-31 | 20.31% | $2.24 Million | $11.03 Million | -17.70pp |
| 2011-12-31 | 38.01% | $4.18 Million | $10.99 Million | +8.00pp |
| 2010-12-31 | 30.02% | $3.23 Million | $10.75 Million | -6.14pp |
| 2009-12-31 | 36.16% | $3.61 Million | $9.98 Million | -1.90pp |
| 2008-12-31 | 38.05% | $3.85 Million | $10.13 Million | -2.46pp |
| 2007-12-31 | 40.52% | $4.22 Million | $10.41 Million | -5.82pp |
| 2006-12-31 | 46.33% | $5.27 Million | $11.36 Million | +6.66pp |
| 2005-12-31 | 39.68% | $3.95 Million | $9.96 Million | +10.82pp |
| 2004-12-31 | 28.85% | $2.75 Million | $9.53 Million | +18.00pp |
| 2003-12-31 | 10.85% | $888.32K | $8.19 Million | +0.38pp |
| 2002-12-31 | 10.48% | $787.05K | $7.51 Million | -- |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavir… Read more